Rui ProvidÃancia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1984380/publications.pdf

Version: 2024-02-01

232 papers

6,151 citations

147566 31 h-index 71 g-index

242 all docs 242 docs citations

times ranked

242

10021 citing authors

#	Article	IF	CITATIONS
1	Initial experience of the High-Density Grid catheter in patients undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2022, 63, 259-266.	0.6	5
2	The use of remote monitoring of cardiac implantable devices during the COVID-19 pandemic: an EHRA physician survey. Europace, 2022, 24, 473-480.	0.7	32
3	An overview of heart rhythm disorders and management in myotonic dystrophy type 1. Heart Rhythm, 2022, 19, 497-504.	0.3	2
4	Catheter ablation for atrial fibrillation. The Cochrane Library, 2022, 2022, .	1.5	0
5	Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases. Drugs, 2022, 82, 311.	4.9	12
6	Ethanol ablation for ventricular arrhythmias: A systematic review and metaâ€analysis. Journal of Cardiovascular Electrophysiology, 2022, 33, 510-526.	0.8	4
7	Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey. Europace, 2022, 24, 860-867.	0.7	14
8	Risk factors for developing pacing induced LV dysfunction: Experience from a tertiary center in the UK. PACE - Pacing and Clinical Electrophysiology, 2022, , .	0.5	0
9	Cardiopulmonary Resuscitation and Defibrillator Use in Sports. Frontiers in Cardiovascular Medicine, 2022, 9, 819609.	1.1	4
10	Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?. Revista Portuguesa De Cardiologia, 2022, 41, 783-789.	0.2	2
11	PolarX Cryoballoon metrics predicting successful pulmonary vein isolation: targets for ablation of atrial fibrillation. Europace, 2022, 24, 1420-1429.	0.7	7
12	Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review. Europace, 2022, 24, 1504-1511.	0.7	4
13	Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace, 2021, 23, 494-495.	0.7	64
14	Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 30.	2.7	27
15	Ablation guided by STARâ€mapping in addition to pulmonary vein isolation is superior to pulmonary vein isolation alone or in combination with CFAE/linear ablation for persistent AF. Journal of Cardiovascular Electrophysiology, 2021, 32, 200-209.	0.8	2
16	OUP accepted manuscript. Europace, 2021, , .	0.7	0
17	OUP accepted manuscript. European Heart Journal Quality of Care & Dinical Outcomes, 2021, , .	1.8	2
18	High sensitivity troponin and COVID-19 outcomes. Acta Cardiologica, 2021, , 1-8.	0.3	16

#	Article	IF	CITATIONS
19	Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observational multicentre study. Europace, 2021, 23, 1409-1417.	0.7	16
20	Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situation. Jmirx Med, 2021, 2, e20617.	0.2	8
21	Antithrombotic treatment management in low stroke risk patients undergoing cardioversion of atrial fibrillation & mp;lt;48 h duration: results of an EHRA survey. Europace, 2021, 23, 1502-1507.	0.7	2
22	Authors' Response to Peer Reviews of "Why We Are Losing the War Against COVID-19 on the Data Front and How to Reverse the Situationâ€. Jmirx Med, 2021, 2, e29421.	0.2	0
23	A multiâ€eenter experience of ablation index for evaluating lesion delivery in typical atrial flutter. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1039-1046.	0.5	4
24	Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis. Europace, 2021, , .	0.7	9
25	A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction DiseaseÂin Patients With Myotonic Dystrophy Type 1. JACC: Clinical Electrophysiology, 2021, 7, 1038-1048.	1.3	8
26	Long-Term Impact of Body Mass Index on Survival of Patients Undergoing Cardiac Resynchronization Therapy: A Multi-Centre Study. American Journal of Cardiology, 2021, 153, 79-85.	0.7	0
27	Highâ€risk features and predictors of unexplained syncope in the young SCDâ€SOS cohort. Journal of Cardiovascular Electrophysiology, 2021, 32, 2737-2745.	0.8	2
28	Atrial fibrillation epidemiology, disparity and healthcare contacts: a population-wide study of 5.6 million individuals. Lancet Regional Health - Europe, The, 2021, 7, 100157.	3.0	23
29	Different methods of providing automatic external defibrillators to out-of-hospital cardiac arrests to prevent sudden cardiac death. The Cochrane Library, 2021, 2021, .	1.5	1
30	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	1.5	28
31	Early mortality after implantable cardioverter defibrillator: Incidence and associated factors. International Journal of Cardiology, 2020, 301, 114-118.	0.8	5
32	Cryoablation for persistent and longstanding persistent atrial fibrillation: results from a multicentre European registry. Europace, 2020, 22, 375-381.	0.7	29
33	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. European Heart Journal, 2020, 41, 1976-1986.	1.0	33
34	Epicardial Ablation in Brugada Syndrome. Cardiac Electrophysiology Clinics, 2020, 12, 345-356.	0.7	6
35	Sameâ€day discharge following catheter ablation of atrial fibrillation: A safe and costâ€effective approach. Journal of Cardiovascular Electrophysiology, 2020, 31, 3097-3103.	0.8	27
36	Efficacy and safety of ablation index-guided catheter ablation for atrial fibrillation: an updated meta-analysis. Europace, 2020, 22, 1659-1671.	0.7	39

#	Article	IF	CITATIONS
37	Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation. The Cochrane Library, 2020, , .	1.5	O
38	Systematic review and network metaâ€analysis of atrial fibrillation percutaneous catheter ablation technologies using randomized controlled trials. Journal of Cardiovascular Electrophysiology, 2020, 31, 2192-2205.	0.8	4
39	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Metaâ€Analysis in Up to 16Â126 Participants. Journal of the American Heart Association, 2020, 9, e013131.	1.6	36
40	Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease. Europace, 2020, 22, 1600-1600.	0.7	2
41	Non–vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2626-2631.	0.8	6
42	Sex-specific efficacy and safety of cryoballoon versus radiofrequency ablation for atrial fibrillation: An individual patient data meta-analysis. Heart Rhythm, 2020, 17, 1232-1240.	0.3	11
43	Non-vitamin K oral anticoagulants at the time of cardiac rhythm device surgery: A systematic review and meta-analysis. Thrombosis Research, 2020, 188, 90-96.	0.8	7
44	Impact of pulmonary vein isolation on mechanisms sustaining persistent atrial fibrillation: Predicting the acute response. Journal of Cardiovascular Electrophysiology, 2020, 31, 903-912.	0.8	8
45	Impact of Type-2 Diabetes Mellitus on the Outcomes of Catheter Ablation of Atrial Fibrillation (European Observational Multicentre Study). American Journal of Cardiology, 2020, 125, 901-906.	0.7	30
46	Predictive Role of BNP/NT-proBNP in Non-Heart Failure Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Systematic Review. Current Medicinal Chemistry, 2020, 27, 4469-4478.	1.2	5
47	Ethnicity and COVID-19 cardiovascular complications: a multi-center UK cohort. American Journal of Cardiovascular Disease, 2020, 10, 455-462.	0.5	3
48	Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Emergencias, 2020, 32, 57-58.	0.6	0
49	Structural remodeling and conduction velocity dynamics in the human left atrium: Relationship with reentrant mechanisms sustaining atrial fibrillation. Heart Rhythm, 2019, 16, 18-25.	0.3	42
50	Fluoroscopy guided axillary vein access versus cephalic vein access in pacemaker and defibrillator implantation: Randomized clinical trial of efficacy and safety. Journal of Cardiovascular Electrophysiology, 2019, 30, 2183-2183.	0.8	0
51	Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 245-250.	0.2	0
52	A nurseâ€ked implantable loop recorder service is safe and cost effective. Journal of Cardiovascular Electrophysiology, 2019, 30, 2900-2906.	0.8	17
53	Impact of Ethnicity on the Prevalence of Early Repolarization Pattern in Children: Comparison Between Caucasian and African Populations. Pediatric Cardiology, 2019, 40, 1553-1558.	0.6	3
54	World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. The Lancet Global Health, 2019, 7, e1332-e1345.	2.9	554

#	Article	IF	CITATIONS
55	Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase). Archives of Cardiovascular Diseases, 2019, 112, 523-531.	0.7	1
56	Atrial Fibrillation Ablation and Reduction of Stroke Events. Stroke, 2019, 50, 2970-2976.	1.0	14
57	Full blood count as potential predictor of outcomes in patients undergoing cardiac resynchronization therapy. Scientific Reports, 2019, 9, 13016.	1.6	4
58	Impact of Body Mass Index on the Outcomes of Catheter Ablation of Atrial Fibrillation: A European Observational Multicenter Study. Journal of the American Heart Association, 2019, 8, e012253.	1.6	38
59	Catheter ablation of atrioventricular nodal re-entrant tachycardia: Humans versus machines?. Revista Portuguesa De Cardiologia, 2019, 38, 193-194.	0.2	0
60	Catheter ablation of atrioventricular nodal re-entrant tachycardia: Humans versus machines?. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 193-194.	0.2	0
61	Science deserves justice: The results of the CABANA trial are positive and support catheter ablation of atrial fibrillation for reducing mortality and hospitalizations. Revista Portuguesa De Cardiologia, 2019, 38, 245-250.	0.2	7
62	Catheter ablation of atrial fibrillation in patients with heart failure with reduced ejection fraction: Real world experience from six European centers. Journal of Cardiovascular Electrophysiology, 2019, 30, 1270-1277.	0.8	6
63	Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. European Heart Journal, 2019, 40, 2121-2127.	1.0	29
64	Prolonged action potential duration and dynamic transmural action potential duration heterogeneity underlie vulnerability to ventricular tachycardia in patients undergoing ventricular tachycardia ablation. Europace, 2019, 21, 616-625.	0.7	17
65	P309R' wave in precordial leads V1-V2 in patients from the young SCD-SOS cohort. European Heart Journal, 2019, 40, .	1.0	0
66	Ventricular tachycardia ablation in structural heart disease: Impact of ablation strategy and non-inducibility as an end-point on long term outcome. International Journal of Cardiology, 2019, 277, 110-117.	0.8	12
67	Differences in the upslope of the precordial body surface ECG T wave reflect right to left dispersion of repolarization in the intact human heart. Heart Rhythm, 2019, 16, 943-951.	0.3	26
68	Catheter ablation for fascicular ventricular tachycardia: A systematic review. International Journal of Cardiology, 2019, 276, 136-148.	0.8	9
69	Left atrial scarring and conduction velocity dynamics: Rate dependent conduction slowing predicts sites of localized reentrant atrial tachycardias. International Journal of Cardiology, 2019, 278, 114-119.	0.8	11
70	Automated detection of repetitive focal activations in persistent atrial fibrillation: Validation of a novel detection algorithm and application through panoramic and sequential mapping. Journal of Cardiovascular Electrophysiology, 2019, 30, 58-66.	0.8	34
71	Inflammatory Biomarkers in Atrial Fibrillation. Current Medicinal Chemistry, 2019, 26, 837-854.	1.2	25
72	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. International Journal of Cardiology, 2018, 260, 82-87.	0.8	20

#	Article	IF	CITATIONS
73	Validation of a novel mapping system and utility for mapping complex atrial tachycardias. Journal of Cardiovascular Electrophysiology, 2018, 29, 395-403.	0.8	18
74	Does presence of left ventricular contractile reserve improve response to cardiac resynchronization therapy? An updated meta-analysis. International Journal of Cardiology, 2018, 252, 224-228.	0.8	4
75	Duration of hospital admission, need of on-demand analgesia and other peri-procedural and short-term outcomes in sub-cutaneous vs. transvenous implantable cardioverter–defibrillators. International Journal of Cardiology, 2018, 258, 133-137.	0.8	7
76	Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. Heart, 2018, 104, 1529-1535.	1.2	20
77	Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis. Europace, 2018, 20, 89-96.	0.7	14
78	Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace, 2018, 20, 682-691.	0.7	60
79	Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis. Europace, 2018, 20, 481-491.	0.7	15
80	Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?. Europace, 2018, 20, f288-f298.	0.7	14
81	Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator?. Europace, 2018, 20, 897-901.	0.7	28
82	Impact of QTc formulae in the prevalence of short corrected QT interval and impact on probability and diagnosis of short QT syndrome. Heart, 2018, 104, 502-508.	1.2	24
83	Biological therapies targeting arrhythmias: are cells and genes the answer?. Expert Opinion on Biological Therapy, 2018, 18, 237-249.	1.4	0
84	A Novel Mapping System for Panoramic Mapping of the Left Atrium. JACC: Clinical Electrophysiology, 2018, 4, 124-134.	1.3	79
85	Empowerment of athletes with cardiac disorders: a new paradigm. Europace, 2018, 20, 1243-1251.	0.7	13
86	Procedural and quality assessment data on catheter ablation for fascicular ventricular tachycardia. Data in Brief, 2018, 21, 2376-2378.	0.5	1
87	P5773Atrial fibrillation catheter ablation in patients with hypertrophic cardiomyopathy: multi-centre experience and application of HCM-Risk SCD score to predict ablation outcome. European Heart Journal, 2018, 39, .	1.0	0
88	Interrupted versus uninterrupted novel oral anticoagulant periâ€implantation of cardiac device: A singleâ€eenter randomized prospective pilot trial. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1476-1480.	0.5	8
89	Catheter ablation for atrial fibrillation on uninterrupted direct oral anticoagulants: A safe approach. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1001-1009.	0.5	6
90	Characterization of drivers maintaining atrial fibrillation: Correlation with markers of rapidity and organization on spectral analysis. Heart Rhythm, 2018, 15, 1296-1303.	0.3	33

#	Article	IF	Citations
91	Cochrane corner: adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Heart, 2018, 104, 1993-1994.	1.2	3
92	Association of catheter ablation for atrial fibrillation with mortality and stroke: A systematic review and meta-analysis. International Journal of Cardiology, 2018, 266, 136-142.	0.8	32
93	Risk Stratification in Brugada Syndrome: Current Status and Emerging Approaches. Arrhythmia and Electrophysiology Review, 2018, 7, 79.	1.3	23
94	Cryoablation of paroxysmal atrial fibrillation displayed the same results as radiofrequency despite anatomical variants of pulmonary veins. Europace, 2017, 19, euw277.	0.7	1
95	Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible?. Europace, 2017, 19, euw080.	0.7	108
96	Subclavian crush syndrome AND subcutaneous ICD in primary prevention patients. Journal of Cardiovascular Medicine, 2017, 18, 717-718.	0.6	2
97	Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. Heart, 2017, 103, 753-760.	1.2	21
98	Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice. Journal of Cardiovascular Electrophysiology, 2017, 28, 666-673.	0.8	14
99	Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	36
100	Is it time to loosen the restrictions on athletes with cardiac disorders competing in sport?. British Journal of Sports Medicine, 2017, 51, 1056-1057.	3.1	6
101	Adding Defibrillation Therapy to CardiacÂResynchronization on the BasisÂofÂthe MyocardialÂSubstrate. Journal of the American College of Cardiology, 2017, 69, 1669-1678.	1.2	56
102	Adenosine-guided pulmonary vein isolation versus conventional pulmonary vein isolation in patients undergoing atrial fibrillation ablation: An updated meta-analysis. International Journal of Cardiology, 2017, 227, 151-160.	0.8	7
103	Call for joint informed consent in athletes with inherited cardiac conditions. Open Heart, 2017, 4, e000516.	0.9	2
104	Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. The Cochrane Library, 2017, 2017, CD005154.	1.5	12
105	The Benefit of Cardiac Resynchronization TherapyÂlsÂNot Hindered by the Number of Comorbidities. Journal of the American College of Cardiology, 2017, 70, 2096-2097.	1.2	4
106	Brugada syndrome is associated with scar and endocardial involvement: Insights from high-density mapping with the Rhythmiaâ,,¢ mapping system. Revista Portuguesa De Cardiologia, 2017, 36, 773.e1-773.e4.	0.2	5
107	Panoramic atrial mapping with basket catheters: A quantitative analysis to optimize practice, patient selection, and catheter choice. Journal of Cardiovascular Electrophysiology, 2017, 28, 1423-1432.	0.8	24
108	The unfinished issue of ischaemic stroke and embolic events during catheter ablation of atrial fibrillation. Europace, 2017, 19, 881-881.	0.7	14

#	Article	IF	CITATIONS
109	Dualâ€site right ventricular pacing in patients undergoing cardiac resynchronization therapy: Results of a multicenter propensityâ€matched analysis. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1113-1120.	0.5	1
110	Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices. American Journal of Cardiology, 2017, 120, 1158-1165.	0.7	12
111	Atrial fibrillation monitoring to reduce thromboembolic risk: Selecting the patient and the monitoring device. Revista Portuguesa De Cardiologia, 2017, 36, 547-549.	0.2	0
112	A propensity matched case–control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. International Journal of Cardiology, 2017, 228, 280-285.	0.8	45
113	Brugada syndrome is associated with scar and endocardial involvement: Insights from high-density mapping with the Rhythmiaâ,,¢ mapping system. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 773.e1-773.e4.	0.2	2
114	Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Womenâ€"Data From a Multicenter French Registry. Journal of the American Heart Association, 2016, 5, .	1.6	46
115	Ventricular stimulus site influences dynamic dispersion of repolarization in the intact human heart. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H545-H554.	1.5	20
116	Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2016, 102, 1533-1543.	1.2	89
117	The ABC risk score for patients with atrial fibrillation. Lancet, The, 2016, 388, 1979-1980.	6. 3	0
118	Outcomes after cryoballoon or radiofrequency ablation for persistent atrial fibrillation: a multicentric propensity-score matched study. Journal of Interventional Cardiac Electrophysiology, 2016, 47, 133-142.	0.6	25
119	Letter by Providencia and Lambiase Regarding Article, "Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death― Circulation, 2016, 133, e459.	1.6	1
120	Ventricular Arrhythmia Burden in Patients With Heart Failure and Cardiac Resynchronization Devices: The Importance of Renal Function. Journal of Cardiovascular Electrophysiology, 2016, 27, 1328-1336.	0.8	4
121	Long-Term Results of Triventricular Versus Biventricular Pacing in Heart Failure. JACC: Clinical Electrophysiology, 2016, 2, 825-835.	1.3	13
122	Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. American Journal of Cardiology, 2016, 118, 1225-1232.	0.7	8
123	Letter by Providencia and Lambiase Regarding Article, "Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction― Circulation, 2016, 133, e691.	1.6	7
124	Persistent Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 67, 2699-2700.	1.2	1
125	Endocardite de dispositivos, revisão com base na experiência de um centro. Revista Portuguesa De Cardiologia, 2016, 35, 351-358.	0.2	2
126	Exercise restrictions for patients with inherited cardiac conditions: Current guidelines, challenges and limitations. International Journal of Cardiology, 2016, 209, 234-241.	0.8	21

#	Article	IF	Citations
127	Outcomes after cryoablation vs. radiofrequency in patients with paroxysmal atrial fibrillation: impact of pulmonary veins anatomy. Europace, 2016, 18, 1343-1351.	0.7	64
128	Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?. International Journal of Cardiology, 2016, 203, 184-186.	0.8	2
129	Authors' reply. Europace, 2015, 17, 1456-1456.	0.7	O
130	Prediction of Nonarrhythmic Mortality inÂPrimary Prevention Implantable Cardioverter-Defibrillator Patients With Ischemic and Nonischemic Cardiomyopathy. JACC: Clinical Electrophysiology, 2015, 1, 29-37.	1.3	13
131	Transvenous Implantable Cardioverterâ€Defibrillator (ICD) Lead Performance: A Metaâ€Analysis of Observational Studies. Journal of the American Heart Association, 2015, 4, .	1.6	56
132	Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. Arquivos Brasileiros De Cardiologia, 2015, 105, 519-26.	0.3	27
133	Impact of Free Thyroxine on the Outcomes of Left Atrial Ablation Procedures. American Journal of Cardiology, 2015, 116, 1863-1868.	0.7	19
134	Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace, 2015, 17, 174-186.	0.7	64
135	Is There Still a Role for Complex Fractionated Atrial Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and Persistent Atrial Fibrillation?. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1017-1029.	2.1	76
136	Comparison between radiofrequency with contact force-sensing and second-generation cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation. Europace, 2015, 17, 718-724.	0.7	135
137	Universal Definition of Myocardial Infarction: Clinical Insights. Cardiology, 2015, 131, 13-21.	0.6	1,946
138	Importance of Implantable Cardioverterâ€Defibrillator Backâ€Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2015, 4, .	1.6	28
139	Padrão de Brugada tipo 1 induzido pela febre. Revista Portuguesa De Cardiologia, 2015, 34, 287.e1-287.e7.	0.2	4
140	Additional value of associating aortic valve calcification to coronary calcium as a gatekeeper for coronary tomography angiography. BMC Cardiovascular Disorders, 2015, 15, 61.	0.7	1
141	Encerramento percutâneo de foramen ovale patente – registo da prevenção da embolia cerebral paradoxal. Revista Portuguesa De Cardiologia, 2015, 34, 151-157.	0.2	2
142	Utilização de cardioversores desfibrilhadores implantáveis em desportistas: revisão sistemática. Revista Portuguesa De Cardiologia, 2015, 34, 411-419.	0.2	2
143	Higher contact-force values associated with better mid-term outcome of paroxysmal atrial fibrillation ablation using the SmartTouchâ,,¢ catheter. Europace, 2015, 17, 56-63.	0.7	41
144	Contact-force guided radiofrequency vs. second-generation balloon cryotherapy for pulmonary vein isolation in patients with paroxysmal atrial fibrillation—a prospective evaluation. Europace, 2015, 17, 225-231.	0.7	117

#	Article	lF	Citations
145	Does minimally invasive also stand for minimal patient risk? Lessons from an upper gastrointestinal endoscopy. BMJ Case Reports, 2014, 2014, bcr2014204048-bcr2014204048.	0.2	O
146	Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. Heart, 2014, 100, 349.1-350.	1.2	2
147	Risk Stratification of Nonvalvular Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 222-223.	0.7	0
148	Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart, 2014, 100, 324-335.	1.2	75
149	'Green light': watch it twice Europace, 2014, 16, 540-540.	0.7	0
150	Real-time assessment of bidirectional block during pulmonary vein cryoablation. Europace, 2014, 16, 1256-1256.	0.7	0
151	Real-time assessment of pulmonary vein disconnection during cryoablation of atrial fibrillation: can it be 'achieved' in almost all cases?. Europace, 2014, 16, 826-833.	0.7	37
152	Improving risk stratification in non-ST-segment elevation myocardial infarction with combined assessment of GRACE and CRUSADE risk scores. Archives of Cardiovascular Diseases, 2014, 107, 681-689.	0.7	6
153	Realâ€Time Contact Force Sensing for Pulmonary Vein Isolation in the Setting of Paroxysmal Atrial Fibrillation: Procedural and 1â€Year Results. Journal of Cardiovascular Electrophysiology, 2014, 25, 130-137.	0.8	146
154	Can cardiac computed tomography predict cardiovascular events in asymptomatic type-2 diabetics?: results of a long term follow-up. BMC Cardiovascular Disorders, 2014, 14, 2.	0.7	14
155	A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thrombosis Research, 2014, 134, 1253-1264.	0.8	48
156	Pulmonary embolism risk stratification: where are we heading?. European Respiratory Journal, 2014, 43, 298-300.	3.1	2
157	Atrial fibrillation in acute pulmonary embolism: prognostic considerations. Emergency Medicine Journal, 2014, 31, 308-312.	0.4	36
158	Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace, 2014, 16, 1137-1144.	0.7	79
159	Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation?. Cardiovascular Ultrasound, 2014, 12, 28.	0.5	33
160	Post-acute management of the acquired long QT syndrome. Postgraduate Medical Journal, 2014, 90, 348-358.	0.9	17
161	Financial impact of adopting implantable loop recorder diagnostic for unexplained syncope compared with conventional diagnostic pathway in Portugal. BMC Cardiovascular Disorders, 2014, 14, 63.	0.7	7
162	Meta-Analysis of the Influence of Chronic Kidney Disease on the Risk of Thromboembolism Among Patients With Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 2014, 114, 646-653.	0.7	63

#	Article	IF	Citations
163	Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. BMC Cardiovascular Disorders, 2013, 13, 40.	0.7	23
164	Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. Clinical Research in Cardiology, 2013, 102, 701-711.	1.5	16
165	Contrast-enhanced multidetector computed tomography: A new prognosticator in acute pulmonary embolism?. Revista Portuguesa De Cardiologia, 2013, 32, 839-840.	0.2	0
166	Letter to the Editorâ€" When to implant an ICD following a myocardial infarction?. Heart Rhythm, 2013, 10, e78.	0.3	0
167	The Role of Echocardiography in Thromboembolic Risk Assessment of Patients with Nonvalvular Atrial Fibrillation. Journal of the American Society of Echocardiography, 2013, 26, 801-812.	1.2	35
168	Early Repolarization and Arrhythmia Death. Journal of the American College of Cardiology, 2013, 61, 2315-2316.	1.2	0
169	Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. Thrombosis Research, 2013, 132, 293-299.	0.8	30
170	The benefit of implantable cardioverter defibrillator programming in MADIT-RIT: more for less?. Europace, 2013, 15, 1229-1230.	0.7	2
171	Chronic renal disease is associated with stroke and thromboembolism in atrial fibrillation independently from gender. International Journal of Cardiology, 2013, 168, 3106-3107.	0.8	4
172	Evaluation of left atrial deformation to predict left atrial stasis in patients with non-valvular atrial fibrillation $\hat{a} \in \hat{a}$ a pilot-study. Cardiovascular Ultrasound, 2013, 11, 44.	0.5	26
173	Cardiac troponin I: Prothrombotic risk marker in non-valvular atrial fibrillation. International Journal of Cardiology, 2013, 167, 877-882.	0.8	24
174	Encerramento percutâneo do apêndice auricular esquerdo para profilaxia de tromboembolismo na fibrilhação auricular em doentes com contraindicação ou falência da hipocoagulação oral: experiência de um serviço. Revista Portuguesa De Cardiologia, 2013, 32, 461-471.	0.2	13
175	Troponin rise and poor outcome in patients presenting to the ED with short-duration atrial fibrillation. American Journal of Emergency Medicine, 2013, 31, 1147-1148.	0.7	0
176	Troponin rise in patients with atrial fibrillation: A marker of adverse prognosis and increased thromboembolic risk. International Journal of Cardiology, 2013, 168, 4889.	0.8	6
177	Percutaneous closure of the left atrial appendage for prevention of thromboembolism in atrial fibrillation for patients with contraindication to or failure of oral anticoagulation: A single-center experience. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 461-471.	0.2	8
178	Clinical correlates of early repolarization and J wave patterns… are they proarrhythmic on their own?. Journal of Electrocardiology, 2013, 46, 73-74.	0.4	0
179	Chronic kidney disease: One step further in the refinement of risk stratification of atrial fibrillation and impact on the choice of anticoagulant. Thrombosis Research, 2013, 132, e158-e160.	0.8	0
180	Encerramento percutâneo do apêndice auricular esquerdo para profilaxia de tromboembolismo na fibrilhação auricular. Revista Portuguesa De Cardiologia, 2013, 32, 311-323.	0.2	2

#	Article	IF	CITATIONS
181	The Use of the Chronic Kidney Disease Epidemiology Collaboration Equation and Global Cardiovascular Risk Assessment in Patients with Atrial Fibrillation. Cardiology, 2013, 124, 220-221.	0.6	1
182	Decreased Glomerular Filtration Rate and Markers of Left Atrial Stasis in Patients with Nonvalvular Atrial Fibrillation. Cardiology, 2013, 124, 3-10.	0.6	31
183	Letter by Providencia et al Regarding Article, "Atrial Fibrillation and the Risk of Ischemic Stroke: Does It Still Matter in Patients With a CHA ₂ DS ₂ -VASc Score of 0 or 1?― Stroke, 2013, 44, e38.	1.0	3
184	Left ventricular mass as a discriminator of left atrial appendage thrombus in persistent atrial fibrillation: promise or over-enthusiasm?. European Heart Journal Cardiovascular Imaging, 2013, 14, 299-299.	0.5	0
185	Fever outperforms flecainide test in the unmasking of type 1 Brugada syndrome electrocardiogram. Europace, 2013, 15, 394-394.	0.7	15
186	Nesidioblastosis: an undescribed cause of transient loss of conscience in young adults. Europace, 2013, 15, 1506-1506.	0.7	2
187	Adjusting treatment to pulmonary vein rare anatomic variants: a box lesion for the ablation of atrial fibrillation in a patient with an atypical common inferior trunk. Europace, 2013, 15, 1420-1420.	0.7	4
188	Too ill for an implantable cardioverter defibrillator?. Europace, 2013, 15, 1226-1226.	0.7	1
189	Early repolarization patterns and the role of additional proarrhythmic triggers. Europace, 2013, 15, 482-485.	0.7	13
190	Early discharge and outpatient treatment of patients admitted for acute pulmonary embolism. European Respiratory Journal, 2013, 41, 486-487.	3.1	0
191	Pulmonary embolism risk stratification. Blood Coagulation and Fibrinolysis, 2013, 24, 896-898.	0.5	4
192	A Review on Stateâ€ofâ€theâ€Art Data Regarding Safe Early Discharge Following Admission for Pulmonary Embolism: What Do We Know?. Clinical Cardiology, 2013, 36, 507-515.	0.7	20
193	Risk Stratification of Patients with Early Repolarization…Still an Unresolved Matter!. Annals of Noninvasive Electrocardiology, 2013, 18, 210-211.	0.5	0
194	The prevalence of left atrial appendage thrombus and spontaneous echocardiographic contrast is positively correlated with the <scp>CHADS</scp> ₂ and <scp>CHA</scp> ₂ <scp>VAS</scp> c scores. European Journal of Neurology, 2013, 20, e84.	1.7	0
195	Excluding the Presence of Left Atrial Thrombus Before Pulmonary Vein Isolation: " <i>primum non nocere</i> â€i. Journal of Cardiovascular Electrophysiology, 2013, 24, E3-5.	0.8	0
196	Is More Aggressive Prevention of Coronary Artery Disease Required for Patients With Early Repolarization Syndrome?. Circulation Journal, 2013, 77, 1642.	0.7	1
197	Cardiovascular disease: thinking beyond atherosclerosis. BMJ Case Reports, 2013, 2013, bcr2013009348-bcr2013009348.	0.2	0
198	Holiday Heart Syndrome Revisited after 34 Years. Arquivos Brasileiros De Cardiologia, 2013, 101, 183-9.	0.3	49

#	Article	IF	Citations
199	Atypical atrial myxoma pending to the left atrial appendage: a diagnostic challenge. BMJ Case Reports, 2013, 2013, bcr2012007850-bcr2012007850.	0.2	1
200	Infecção recorrente em apresentação tardia de taquicardia ventricular polimórfica catecolaminÃ@rgica. Arquivos Brasileiros De Cardiologia, 2013, 100, e4-e7.	0.3	1
201	Mean corpuscular volume and red cell distribution width as predictors of left atrial stasis in patients with non-valvular atrial fibrillation. American Journal of Cardiovascular Disease, 2013, 3, 91-102.	0.5	9
202	Early Repolarization and Sudden Cardiac Death Due to an Acute Coronary Event. Circulation: Arrhythmia and Electrophysiology, 2012, 5, e116; author reply e117-8.	2.1	0
203	Manchester triage in acute pulmonary embolism: can it unmask the grand impersonator?. Emergency Medicine Journal, 2012, 29, e6-e6.	0.4	7
204	ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 320-336.	0.4	9
205	Mitral regurgitation during a myocardial infarction – New predictors and prognostic significance at two years of follow-up. Acute Cardiac Care, 2012, 14, 27-33.	0.2	7
206	Cardioversion safety in patients with nonvalvular atrial fibrillation. Blood Coagulation and Fibrinolysis, 2012, 23, 597-602.	0.5	19
207	Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. Europace, 2012, 14, 36-45.	0.7	64
208	Should We Rely on Risk Assessment by the CHADS2 Score in Patients With Non-Valvular Atrial Fibrillation Undergoing Direct Current Cardioversion?. American Journal of Cardiology, 2012, 110, 468-469.	0.7	0
209	Is there a need for adjusting the results of the recent meta-analysis on the novel oral anticoagulants in atrial fibrillation to the baseline CHADS2 score?. International Journal of Cardiology, 2012, 159, 161-162.	0.8	3
210	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a rebuttal. Journal of Thrombosis and Haemostasis, 2012, 10, 2913-2913.	1.9	2
211	LR–PED Rule: Low Risk Pulmonary Embolism Decision Rule – A new decision score for low risk Pulmonary Embolism. Thrombosis Research, 2012, 130, 327-333.	0.8	26
212	Thoracic aortic aneurysm causing platypnoea and dorsalgia. BMJ Case Reports, 2012, 2012, bcr0220125879-bcr0220125879.	0.2	0
213	Non-Hodgkin's lymphoma presenting as a mediastinal mass in a 38-year-old patient with superior vena cava syndrome and extreme fatigue owing to left atrium and right ventricle outflow tract compression: the applicability of strain imaging. BMJ Case Reports, 2012, 2012, bcr0220125880-bcr0220125880.	0.2	O
214	Perforation of the right ventricle during cardiac resynchronisation therapy upgrade not related to a coexisting persistent left superior vena cava. BMJ Case Reports, 2012, 2012, bcr2012006299-bcr2012006299.	0.2	0
215	Impending paradoxical embolism with a thrombus crossing a patent foramen ovale. BMJ Case Reports, 2012, 2012, bcr2012006662-bcr2012006662.	0.2	5

Thromboembolic Risk in Atrial Flutter Resembles Non-Valvular Atrial Fibrillation (Insights from) Tj ETQq0 0 0 rgBT /Oyerlock 19 Tf 50 62

#	Article	IF	Citations
217	Challenging pulmonary embolism - A new generation of oral anticoagulants. Journal of Thoracic Disease, 2012, 4, 244-6.	0.6	2
218	Risk stratification of patients with atrial fibrillation: Biomarkers and other future perspectives. World Journal of Cardiology, 2012, 4, 195.	0.5	7
219	A CHADS(2) score of zero is not necessarily associated to a low risk of thromboembolic events. American Journal of Cardiovascular Disease, 2012, 2, 150-1.	0.5	O
220	Transient loss of consciousness in young adults. International Journal of Cardiology, 2011, 152, 139-143.	0.8	14
221	Thirteen square centimetre mass causing syncope in a patient with device related infective endocarditis. BMJ Case Reports, 2011, 2011, bcr1020114943-bcr1020114943.	0.2	O
222	Multidetector CT of rare isolated partial anomalous pulmonary venous return. BMJ Case Reports, 2011, 2011, bcr1020103381-bcr1020103381.	0.2	3
223	Importance of Manchester Triage in acute myocardial infarction: impact on prognosis. Emergency Medicine Journal, 2011, 28, 212-216.	0.4	16
224	Corrected ASD: case closed?. BMJ Case Reports, 2011, 2011, bcr0120113714-bcr0120113714.	0.2	0
225	Telangiectasia hereditária hemorrágica: causa rara de hipertensão pulmonar?. Arquivos Brasileiros De Cardiologia, 2010, 94, e94-e96.	0.3	4
226	Headache and cardiovascular disease: old symptoms, new proposals. Future Cardiology, 2010, 6, 703-723.	0.5	1
227	Cardiac MDCT assessment of compression of the left main stem by a dilated pulmonary trunk. Revista Portuguesa De Cardiologia, 2010, 29, 893-4.	0.2	О
228	Screening for warning signs of sudden cardiac death in the young: the SCD-SOS questionnaire. Revista Portuguesa De Cardiologia, 2010, 29, 1191-205.	0.2	2
229	Pulmonary hypertension in patients with ostium secundum atrial septal defect-is it related to echocardiographic complexity?. Revista Portuguesa De Cardiologia, 2009, 28, 1087-96.	0.2	3
230	Aquarium sign in sepsis. European Heart Journal Cardiovascular Imaging, 2008, 9, 336-337.	0.5	2
231	External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis. The Cochrane Library, 0, , .	1.5	0
232	Defining electrocardiographic criteria to differentiate nonâ€type 1 Brugada ECG variants from normal incomplete RBBB patterns in the young SCDâ€SOS cohort. Journal of Cardiovascular Electrophysiology, 0, , .	0.8	1